Vaxxinity to Present at Upcoming Investor Conferences in November
November 01, 2022 09:00 ET
|
Vaxxinity, Inc.
DALLAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu,...
Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia
October 24, 2022 08:00 ET
|
Vaxxinity, Inc.
UB-612 Phase 3 topline data readout expected in 4Q22 DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine
September 13, 2022 08:00 ET
|
Vaxxinity, Inc.
DALLAS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first...
Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK)
September 12, 2022 08:00 ET
|
Vaxxinity, Inc.
DALLAS, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that it has...
Vaxxinity to Present at Upcoming Investor Conferences in September
September 01, 2022 08:00 ET
|
Vaxxinity, Inc.
DALLAS, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu,...
Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
August 11, 2022 08:00 ET
|
Vaxxinity, Inc.
• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth Quarter of 2022 • UB-312 Phase 1 Part B Trial for Parkinson’s Completes Last Patient Last Dose, and Remains...
Vaxxinity to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 04, 2022 07:00 ET
|
Vaxxinity, Inc.
DALLAS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu,...
Vaxxinity’s Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates
August 02, 2022 08:00 ET
|
Vaxxinity, Inc.
Results support Anti-PCSK9 vaccine approach to treat hypercholesterolemia by lowering LDL cholesterolVXX-401 selected as Lead Candidate to treat hypercholesterolemia DALLAS, Aug. 02, 2022 (GLOBE...
Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates at the 2022 Alzheimer's Association International Conference (AAIC)
August 01, 2022 08:00 ET
|
Vaxxinity, Inc.
DALLAS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, presented new preclinical data on...
Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines
July 25, 2022 11:57 ET
|
Vaxxinity, Inc.
Summit is taking place July 26, 2022 from 11:00 AM ET – 3:15 PM ET The White House Summit on the Future of COVID-19 Vaccines live webcast can be accessed here DALLAS, July 25, 2022 (GLOBE...